share_log

STRATA Skin Sciences Announces Renewal of Exclusive Distribution Agreements in China and Japan

STRATA Skin Sciences Announces Renewal of Exclusive Distribution Agreements in China and Japan

STRATA Skin Sciences宣佈續訂中國和日本的獨家分銷協議
GlobeNewswire ·  04/09 08:30

Distributors in China and Japan have each maintained exclusive distribution agreements with the Company for over 10 years and collectively accounted for 46% of the Company's total international revenue in 2023

中國和日本的分銷商均與公司簽訂了超過10年的獨家分銷協議,合計佔公司2023年國際總收入的46%

HORSHAM, Pa., April  09, 2024  (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the renewal of two distinct distribution agreements in international territories – one with the current exclusive distributor in China and a second with the current exclusive distributor in Japan. Terms of each of the distribution agreements are for three years and carry minimum unit placements and/or purchases of the XTRAC and VTRAC devices.

賓夕法尼亞州霍舍姆,2024年4月9日(GLOBE NEWSWIRE)——致力於開發、商業化和營銷用於治療皮膚病的創新產品的醫療技術公司STRATA Skin Sciences, Inc.(“STRATA” 或 “公司”)(納斯達克股票代碼:SSKN)宣佈在國際地區續訂兩項不同的分銷協議——一項與目前的中國獨家分銷商續訂在日本。每份分銷協議的條款均爲三年,包括XTRAC和VTRAC設備的最低單位投放和/或購買。

"The renewal of these exclusive distribution agreements in China and Japan, when coupled with the renewal of the distribution agreement in South Korea announced in December 2023, brings improved visibility to the international segment of our business," stated Dr. Dolev Rafaeli, STRATA's President and Chief Executive Officer. "International revenue in 2023 was nearly a third of our total revenue, and as we focus on additional opportunities for growth outside of the U.S., we are gratified that our long-standing exclusive distributors in these three key territories continue to provide value through our innovative product offerings in their respective dermatology markets. We look forward to continued mutually beneficial relations with each and leveraging our installed base around the world, as service and parts sales are an important aspect of our international business."

STRATA總裁兼首席執行官多列夫·拉斐利博士表示:“在中國和日本續訂這些獨家分銷協議,加上2023年12月宣佈續訂的韓國分銷協議,提高了我們國際業務的知名度。”“2023年的國際收入佔我們總收入的近三分之一,隨着我們專注於美國以外的更多增長機會,我們對我們在這三個關鍵領域的長期獨家分銷商繼續通過我們在各自的皮膚科市場提供的創新產品提供價值感到高興。我們期待與雙方繼續保持互利關係,並充分利用我們在全球的安裝基礎,因爲服務和零件銷售是我們國際業務的重要方面。”

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論